Brexanolone

Biotech stocks had a fairly decent outing in February, with the iShares NASDAQ Biotechnology Index (NASDAQ: IBB) adding roughly 2.7 percent for the month compared to the 3 percent gain for the S&P 500 Index. After the government shutdown-related slackness in January, FDA review picked up in...

Sage Therapeutics Inc (NASDAQ: SAGE) is a buy ahead of the commercial launch of its safer alternatives to existing antidepressants, according to Ladenburg Thalmann. The Analyst Ladenburg Thalmann's Michael Higgins initiated coverage of Sage Therapeutics' stock with a Buy rating and $...

SAGE Therapeutics Inc (NASDAQ: SAGE) has had a laudable 109-percent run in recent months after meeting primary endpoints in multiple trials and securing regulatory approvals.  It found further reason to celebrate Monday with the conversion of a new Street advocate. The Rating Morgan Stanley...

Shares of SAGE Therapeutics Inc (NASDAQ: SAGE) plunged Tuesday after the biopharma company announced its treatment for super-refractory status epilepticus failed its phase III trial. Chardan analyst Gbola Amusa rated the stock a Hold and said a price target was under review. Shares Fall Off A Cliff...